Symbolbild · KI-generiert
Relmada Therapeutics, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Relmada Therapeutics is a clinical-stage pharmaceutical company developing treatments for central nervous system disorders, in particular major depressive disorder. Its lead candidate REL-1017 (Esmethadone) is an NMDA receptor antagonist that has been investigated in clinical trials for treatment-resistant depression. The company has no approved products on the market.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Relmada Therapeutics, Inc. | RLMD | NASDAQ | 557 Mio. USD |
| Altimmune, Inc. | ALT | NASDAQ | 552 Mio. USD |
| Zevra Therapeutics, Inc. | ZVRA | NASDAQ | 562 Mio. USD |
| Mesa Laboratories, Inc. | MLAB | NASDAQ | 564 Mio. USD |
| Cytek Biosciences, Inc. | CTKB | NASDAQ | 545 Mio. USD |
| Shattuck Labs, Inc. | STTK | NASDAQ | 542 Mio. USD |
| Beta Bionics, Inc. | BBNX | NASDAQ | 577 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.